FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024375382> ?p ?o ?g. }

• W2024375382 endingPage "185" @default.
• W2024375382 startingPage "185.1" @default.
• W2024375382 abstract "<h3>Background</h3> 24-week data from ACT-RAY comparing an add-on strategy (TCZ+MTX) with a switch strategy (TCZ+placebo [PBO]) in MTX-IR patients have been previously reported, demonstrating relevant clinical and radiographic benefit without a statistically significant difference between the 2 groups. Longer-term data are needed to assess the 2 strategies over time and the effect of the protocol-specified treat-to-target strategy after Week 24. <h3>Objectives</h3> To assess the 52 week efficacy and safety of a TCZ-based adaptive treatment strategy with and without MTX in adult patients with moderate to severe RA and an inadequate response to MTX. <h3>Methods</h3> ACT-RAY is a phase 3b clinical trial. Patients on stable doses of MTX were randomized to either add TCZ 8 mg/kg IV every 4 weeks to their existing MTX or switch to TCZ 8 mg/kg IV every 4 weeks with oral PBO. Open-label DMARDs other than MTX were added at Week 24 or later, usually if DAS28 was >3.2, maintaining blinding of MTX/PBO. Groups are labeled “TCZ+MTX” and “TCZ+PBO” despite treatment modifications in both groups. <h3>Results</h3> 556 patients were randomized, with 85% completing 52 weeks of treatment. Baseline data were similar between the 2 groups except for Genant-modified Sharp Score, which was higher in the TCZ+PBO group. Between weeks 24 and 52, the proportion of patients receiving DMARD intensification was comparable in the TCZ+MTX and TCZ+PBO arms (29% vs 33%). Efficacy results are shown in the table. Efficacy was maintained or improved from Week 24 to 52. Most patients had no radiographic progression from baseline to 52 weeks >1.5 (smallest detectable change [SDC]). Rates of SAEs and serious infections per 100 PY were 14.2 and 4.9 for TCZ+MTX and 17.7 and 6.3 for TCZ+PBO, respectively. In patients with normal baseline values, ALT elevations >60U/L were observed in 36% of TCZ+MTX and 17% of TCZ+PBO patients. Antidrug antibodies (ADAs) were detected in 4.7% of patients (10/215) in the TCZ+MTX group and 5.4% (11/204) in the TCZ+PBO group up to week 52. Neutralizing ADAs were detected in 3.7% of patients (8/215) in the TCZ+MTX group and 4.4% (8/204) in the TCZ+PBO. <h3>Conclusions</h3> Clinical improvements at Week 24 in both groups were maintained or further improved up to Week 52, with the proportion of patients receiving DMARD intensification comparable between TCZ+MTX and TCZ+PBO. The vast majority of patients showed no radiographic progression of structural damage. The proportion of patients with ADAs was similar in both groups. Generally there were no differences in safety between the 2 groups. These data support the possibility of using TCZ monotherapy in patients with contraindications or intolerance to MTX. <h3>Disclosure of Interest</h3> M. Dougados Grant/Research support from: Roche, Consultant for: Roche, K. Kissel Employee of: F. Hoffmann-La Roche Ltd., P. Conaghan Grant/Research support from: Centocor Inc., Roche, Speakers Bureau: Astra Zeneca, Bioberica, Bristol-Meyers Squibb, Centocor Inc., Merck, Novartis, Pfizer, Roche, E. Martin-Mola Consultant for: Abbott Immunology, Roche MSD, Pfizer, UCB, G. Schett Consultant for: Roche, H. Amital: None Declared, R. Xavier Consultant for: Pfizer, Speakers Bureau: Pfizer, Roche, Merck, O. Troum Grant/Research support from: Genentech, Consultant for: Genentech, C. Bernasconi Employee of: F. Hoffmann-La Roche Ltd., T. J. Huizinga Consultant for: Abbott Immunology, Axis Shield Diagnostics, Biotest AG, Bristol-Meyers Squibb, Crescendo Bioscience, Roche, Novartis, Schering-Plough, UCB, Wyeth-Pfizer" @default.
• W2024375382 created "2016-06-24" @default.
• W2024375382 creator A5001936700 @default.
• W2024375382 creator A5004025365 @default.
• W2024375382 creator A5008067100 @default.
• W2024375382 creator A5015160683 @default.
• W2024375382 creator A5040974215 @default.
• W2024375382 creator A5043219883 @default.
• W2024375382 creator A5072427161 @default.
• W2024375382 creator A5075261558 @default.
• W2024375382 creator A5077099389 @default.
• W2024375382 creator A5091696679 @default.
• W2024375382 date "2013-06-01" @default.
• W2024375382 modified "2023-10-01" @default.
• W2024375382 title "THU0093 Clinical, radiographic, and immunogenic effects after 1 year of tocilizumab (TCZ)-based treatment strategy with and without methotrexate (MTX) in RA: The act-ray study" @default.
• W2024375382 doi "https://doi.org/10.1136/annrheumdis-2012-eular.2058" @default.
• W2024375382 hasPublicationYear "2013" @default.
• W2024375382 type Work @default.
• W2024375382 sameAs 2024375382 @default.
• W2024375382 citedByCount "8" @default.
• W2024375382 countsByYear W20243753822012 @default.
• W2024375382 countsByYear W20243753822013 @default.
• W2024375382 countsByYear W20243753822014 @default.
• W2024375382 countsByYear W20243753822015 @default.
• W2024375382 countsByYear W20243753822020 @default.
• W2024375382 crossrefType "journal-article" @default.
• W2024375382 hasAuthorship W2024375382A5001936700 @default.
• W2024375382 hasAuthorship W2024375382A5004025365 @default.
• W2024375382 hasAuthorship W2024375382A5008067100 @default.
• W2024375382 hasAuthorship W2024375382A5015160683 @default.
• W2024375382 hasAuthorship W2024375382A5040974215 @default.
• W2024375382 hasAuthorship W2024375382A5043219883 @default.
• W2024375382 hasAuthorship W2024375382A5072427161 @default.
• W2024375382 hasAuthorship W2024375382A5075261558 @default.
• W2024375382 hasAuthorship W2024375382A5077099389 @default.
• W2024375382 hasAuthorship W2024375382A5091696679 @default.
• W2024375382 hasConcept C126322002 @default.
• W2024375382 hasConcept C142724271 @default.
• W2024375382 hasConcept C168563851 @default.
• W2024375382 hasConcept C204787440 @default.
• W2024375382 hasConcept C27081682 @default.
• W2024375382 hasConcept C2777178219 @default.
• W2024375382 hasConcept C2777575956 @default.
• W2024375382 hasConcept C2781059491 @default.
• W2024375382 hasConcept C535046627 @default.
• W2024375382 hasConcept C71924100 @default.
• W2024375382 hasConcept C90924648 @default.
• W2024375382 hasConceptScore W2024375382C126322002 @default.
• W2024375382 hasConceptScore W2024375382C142724271 @default.
• W2024375382 hasConceptScore W2024375382C168563851 @default.
• W2024375382 hasConceptScore W2024375382C204787440 @default.
• W2024375382 hasConceptScore W2024375382C27081682 @default.
• W2024375382 hasConceptScore W2024375382C2777178219 @default.
• W2024375382 hasConceptScore W2024375382C2777575956 @default.
• W2024375382 hasConceptScore W2024375382C2781059491 @default.
• W2024375382 hasConceptScore W2024375382C535046627 @default.
• W2024375382 hasConceptScore W2024375382C71924100 @default.
• W2024375382 hasConceptScore W2024375382C90924648 @default.
• W2024375382 hasIssue "Suppl 3" @default.
• W2024375382 hasLocation W20243753821 @default.
• W2024375382 hasOpenAccess W2024375382 @default.
• W2024375382 hasPrimaryLocation W20243753821 @default.
• W2024375382 hasRelatedWork W189077404 @default.
• W2024375382 hasRelatedWork W2045253669 @default.
• W2024375382 hasRelatedWork W2053109122 @default.
• W2024375382 hasRelatedWork W2098703756 @default.
• W2024375382 hasRelatedWork W2560320384 @default.
• W2024375382 hasRelatedWork W2739075544 @default.
• W2024375382 hasRelatedWork W2970100988 @default.
• W2024375382 hasRelatedWork W3082559196 @default.
• W2024375382 hasRelatedWork W3139028834 @default.
• W2024375382 hasRelatedWork W3209686377 @default.
• W2024375382 hasVolume "71" @default.
• W2024375382 isParatext "false" @default.
• W2024375382 isRetracted "false" @default.
• W2024375382 magId "2024375382" @default.
• W2024375382 workType "article" @default.